Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Merck’s Molnupiravir Set To Lead Forecast $6bn COVID-19 Oral Antiviral Market
Pfizer and Roche Also In The Running
Oct 06 2021
•
By
Andrew McConaghie
Merck & Co and Ridgeback's antiviral is taken twice a day for 10 days, but must be administered within five days of mild-to-moderate symptoms emerging.
Keep up with the top pharma business news of the week. On the go.
Scrip brings you a weekly bulletin of top picks.
More from Business
More from Scrip